

24 週間投与 4 例。HBe 抗原陰性例では、ペグインターフェロン α 2a 180 μ g 週 1 回 48 週間投与 2 例、90 μ g 48 週間投与 3 例。

効果判定(著効)は HBe 抗原陽性例では、ALT 30 U/L 未満、HBe 抗原 seroconversion、HBV DNA 5.0 Log copies/mL 未満が 6 か月以上持続、HBe 抗原陰性例では、ALT 30 U/L 未満、HBV DNA 4.3 Log copies/mL 未満が 6 か月以上持続とし終了後 6 か月後、1 年後、2 年後、3 年後、4 年後に判定した。他治療に移行した場合は、移行時点で非著効と判定した。

(倫理面への配慮)

臨床試験の目的・方法、副作用、患者に関する個人情報、守秘義務、患者の権利保護等について説明し同意を文章または口頭にて取得し研究を行った。

C. 研究結果

(1) 終了 4 年後までの治療成績

HBe 抗原陽性例の 3 年目、4 年目の著効例は 3 例(3/14;21%)であった。著効例の genotype は A 1 例、C 2 例であり、いずれも 48 週間投与(90 μ g 2 例、180 μ g 1 例)であった。この 3 例の年齢、性別は 26 歳男性、30 歳女性、34 歳男性であった。HBe 抗原陰性例では、2 年目、3 年目、4 年目の著効例は 1 例(1/5;20%)であり、genotype は C で 90 μ g 投与であった。

(2) HBs 抗原量の推移

HBe 抗原陽性例(平均値)では、開始時 3.62 Log/mL、治療終了時 3.12 Log/mL、48 週後 3.52 Log/mL であった。HBe 抗原陰性例では、開始時 3.10 Log/mL、治療終了時 2.68 Log/mL、48 週後 2.67 Log/mL であった。HBe 抗原陽性例では、投与中 0.5~1.0 Log/mL の低下を認めたが投与終了後 48 週では、ほぼ投与前の値に戻った。HBe 抗原陰性例では、5 例中 4 例で 48 週間後 HBs 抗原量の低下がみられた。HBe 抗原陰性の 1 例(37 歳、男性、genotype C)で投与後 3.5 年後に HBs 抗原の陰性化を認めた。

(3) ペグインターフェロン投与終了後の経過(他治療への移行例も含む)

開始時 HBe 抗原陽性例 17 例中投与中または投与終了後に HBe 抗原が陰性化した症例は 5 例であった。このうち 3 例が著効であり、2 例は転院等の経過観察中断であった。残り 12 例は、再度インターフェロン(従来型)治療を行った症例が 6 例、エンテカビル治療を行った症例が 5 例、経過観察中断 1 例であった。インターフェロン治療を行った 6 例中 3 例とエンテカビル治療の 5 例中 4 例で HBe 抗原の陰性化が認められた。一方 HBe 抗原陰性例 5 例では、1 例が HBs 抗原の陰性化を認め、残り 4 例中 2 例でインターフェロン療法、2 例でエンテカビル治療を行った。2 回目のインターフェロン治療をおこなった 1 例でその後 HBs 抗原の陰性化が得られた。

D. 考察

B 型慢性肝炎に対するペグインターフェロン α 2a 24 週間または 48 週間投与の長期成績を検討した。HBe 抗原陽性例の長期成績では、48 週間投与例の 3 例から 4 年後の著効例が認められた。この 3 例はいずれも 35 歳未満であった。一方 HBe 抗原陰性例からは、1 例 HBs 抗原陰性化を認め著効となった。

HBs 抗原量に関しては HBe 抗原陽性例では、ペグインターフェロン α 2a 製剤投与中は、低下を認めるものの投与終了後開始前とほぼ同じ値にもどる症例が多かった。

一方、その後の治療を含めた経過では、HBe 抗原陽性例でインターフェロンまたはエンテカビル投与にて HBe 抗原の陰性化が多くの症例で認められていた。このことは、ペグインターフェロン投与後も肝機能の推移を見ながら、追加治療を行うことによって効果が得られる可能性が高いと考えられる。また HBe 抗原陰性例でもその後のインターフェロンにて HBs 抗原の陰性化を 1 例で認めたことから、同様の傾向があるものと考えられる。

E. 結論

B型慢性肝炎に対するペグインターフェロン α 2a 24週間または48週間投与の長期成績を検討した。HBe抗原陽性例の3年目、4年目の著効例は3例(3/14;21%)、HBe抗原陰性例では、2年目、3年目、4年目の著効例は1例(1/5;20%)であった。HBe抗原陰性の1例で投与後3.5年後にHBs抗原の陰性化を認めた。

F. 健康危険情報

特記すべきことなし。

G. 研究発表

1.論文発表

1. Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. *J Med Virol.* 2014;86:131-8.
2. Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. *J Gastroenterol.* 2013 in press.
3. Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. *J Gastroenterol.* 2013 in press.
4. Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N,

Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. *J Gastroenterol.* 2013 in press.

5. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology.* 2013;58:98-107.
6. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. *J Gastroenterol.* 2013;48:930-41.

2.学会発表

梶木慶一、鈴木文孝、福島泰斗、田中崇、原 祐、川村祐介、瀬崎ひとみ、保坂哲也、芥田憲夫、小林正宏、斉藤聡、鈴木義之、荒瀬康司、池田健次、小林万利子、茶山一彰、熊田博光。B型慢性肝炎に対するペグインターフェロン α 2a の長期治療成績、第40回日本肝臓学会西武会、岐阜、2013.12.6.

H. 知的財産権の出願・登録状況

今回の研究内容については特になし。

IV. 研究成果の刊行に関する一覧表

IV. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
芥田憲夫 熊田博光	肝疾患治療薬 －B型・C型肝炎にお ける抗ウイルス療法 ・抗炎症療法		治療薬ハンドブ ック2013薬剤選 択と処方のポイント	じほう	東京	2013	538-543
鈴木文孝 熊田博光	B型慢性肝炎		消化器疾患最新 の治療2013-2014	南江堂	東京	2013	308-311
岡上 武、 島 俊英、 水野雅之	DAA時代のPNALT 治療方針は？	坂本直哉、 上野義之	肝胆膵。特集C型 肝炎治療2014・経 口抗ウイルス剤 時代の到来	アークメディア	東京	2013	1016- 1020
岡上 武	B型肝炎の治療学	小池和彦	細胞。特集肝臓治 療学	ニュー サイエンス社	東京	2013	220-223
狩野吉康、 小関 至、 豊田成司			C型肝炎に対す る三剤併用療法 (テラプレビル/ ペグインターフ ェロン/リバビリ ン)のすすめかた と留意点	文光堂		2013	313-316
四柳 宏	HBV感染の臨床経過	持田智	de novo B型肝 炎	医薬ジャーナル社	大阪市	2013	44-54
四柳 宏	B型肝炎の感染経路 と対策	田中榮司	B型肝炎の診療 を極める	文光堂	東京都	2013	22-26
坂本穰、 榎本信幸	慢性肝炎・肝硬変(C 型)	一瀬雅夫、 岡政志、 持田智	治療過程で一 目でわかる消化 器薬物療法 STEP 1・2・3	メジカル ビュー社	東京	2013	174-178
辰巳明久、 坂本穰、 榎本信幸	メタボ肝癌とファイ ブロスキャン	小俣政男	メタボ肝癌	アークメディア	東京	2013	163-168
坂本穰、 榎本信幸	C型肝炎	浅香正博、 菅野健太郎、 千葉勉	カラー版消化器 病学 基礎と臨 床	西村書店	東京	2013	1177- 1188
吉岡健太郎	α1-アンチトリプシ ン欠乏症	矢崎義雄	内科学(第10版)	朝倉書店	東京	2013	69-70
吉岡健太郎	肝腫大	矢崎義雄	内科学(第10版)	朝倉書店	東京	2013	1162- 1163
吉岡健太郎	Wilson病	小俣政男、 千葉勉	専門医のための 消化器病学第2 版	医学書院	東京	2013	399-401

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
吉岡健太郎	ヘモクロマトーシス	小俣政男、 千葉勉	専門医のための 消化器病学第 2 版	医学書院	東京	2013	401-403
清家正隆	薬物療法：インスリン センシタイザー	竹原徹郎・ 持田 智	HEPATOLOGY PRACTICE 2	文光堂	東京	2013	185-190
清家正隆	C型肝硬変症に対す るPSE併用IFNの有 用性	犬山シンポ ジウム記録 刊行会 編	第 29 回犬山シン ポジウム ウイ ルス肝炎・肝癌の 病態と治療	メディカルト レビューン	東京	2013	53-62

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, McPhee F, Eric Hughes, <u>Kumada H</u>	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options	J Hepatol.	58	655-662	2013
Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F, <u>Kumada H</u>	Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b	J Viral Hepat.	20	167-173	2013
Tadokoro K, Kobayashi M, Suzuki F, Tanaka C, Yamaguchi T, Nagano M, Egashira T, <u>Kumada H</u>	Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay	J Virol Methods.	189	221-227	2013
Arase Y, Kobayashi M, Suzuki F, Tanaka C, Yamaguchi T, Nagano M, Egashira T, <u>Kumada H</u>	Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C	Hepatology.	3	964-973	2013
Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Dennis Hernandez, Fei Yu, Fiona McPhee, <u>Kumada H</u>	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir	J Hepatol.	58	646-654	2013
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsusima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, <u>Kumada H</u>	Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study	J Gastroenterol.	48	382-390	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hirakawa M, Ikeda K, Kobayashi M, Kawamura Y, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, <u>Kumada H</u>	Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle hepatocellular carcinoma	Hepatol Res.	43	846-852	2013
Osaki Y, Ikeda K, Izumi N, Yamashita S, <u>Kumada H</u> , Hatta S, Okita K	Clinical effectiveness of bipolar radiofrequency ablation for small liver cancer	J Gastroenterol.	48	874-883	2013
Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, <u>Kumada H</u>	Exploratory Study on telaprevir given every 8h at 500mg or 750mg with peginterferon-alpha-2b and rivavirin in hepatitis C patients	Hepatol Res.	43	691-701	2013
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H</u>	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection	Hepatology.	58	98-107	2013
Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, <u>Kumada H</u>	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B	Hepatol Res.	43	596-604	2013
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u>	Emergence of Telaprevir-Resistant Variants Detected by Ultra-Deep Sequencing After Triple Therapy in Patients Infected With HCV Genotype 1	J Med Virol.	85	1028-1036	2013
Nakano R, Maekawa T, Abe H, Hayashi Y, Ochi H, Tsunoda T, <u>Kumada H</u> , Kamatani N, Nakamura Y, Chayama K	Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C	J Gen Virol.	94	81-89	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takaguchi K, Moriwaki H, Doyama H, Iida M, Yagura M, Shimada N, Kang M, Yamada H, Kumada H	Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis	Hepatol Res.	43	459-466	2013
Mimura Y, Richard L Theriault, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, Takano T	The Safety of Chemotherapy Breast Cancer Patients with Hepatitis C Virus Infection	J Cancer.	4	519-523	2013
Torii H, Sueki H, Kumada H, Sakurai Y, Aoki K, Yamada I, Otsuki M	Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan	J Dermatol.	40	1-9	2013
Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H	Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis	Hepatol Int.	7	850-858	2013
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Kumada H	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma	Hepatol Res.	43	942-949	2013
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study	J Gastroenterol.	48	930-941	2013
Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1	J Clin Microbiol.	51	2862-2868	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, <u>Kumada H</u>	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine	J Gastroenterol.		Epub ahead of print	2013
Akuta N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u>	Utility of Telaprevir-Resistant Variant Detection for Prediction of Treatment Efficacy in HCV Genotype 1.	J Clin Microbiol.		Epub ahead of print	2013
Kawakami Y, Suzuki F, Karino Y, Toyota J, <u>Kumada H</u> , Chayama K	Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antivir Ther.		Epub ahead of print	2013
Arase Y, Kobayashi M, Kawamura Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, <u>Kumada H</u> , Kobayashi T	Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.	J Med Virol.	86	169-175	2014
Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, <u>Kumada H</u>	Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis	J Med Virol.		Epub ahead of print	2013
Hosaka T, Suzuki F, <u>Kumada H</u>	Does long-term entecavir treatment really reduce hepatocellular carcinoma incidence in patients with hepatitis B virus infection?	Hepatology.		Epub ahead of print	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kawakami Y, Ikeda K, Fukushima T, Hara T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H</u>	Potential of no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: an experimental animal study.	Hepatol Res.		Epub ahead of print	2013
Kawamura Y, Ikeda K, Fukushima T, Seko Y, Hara T, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H</u>	What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.	Gut Liver.	5	576-584	2013
Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Tsubouchi H, <u>Kumada H</u>	Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.	Hepatol Res.		Epub ahead of print	2013
Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka, Kobayashi M, Saitoh, <u>Kumada H</u>	A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic Hepatitis C.	J Med Virol.	85	1746-1753	2013
Sasaki K, Matsuda M, Kawamura Y, Inoue M, Hashimoto M, Ikeda K, <u>Kumada H</u> , Watanabe G	Factors associated with cancer-related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion	J Hepatobiliary Pancreat Sci.		Epub ahead of print	2013
Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H</u>	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up	J Gastroenterol.		Epub ahead of print	2013
Abe T, Hashiguchi A, <u>Kumada H</u> , Yamazaki K, Ebinuma H, Saito H, Izumi N, Masaki N, Sakamoto M	Quantification of collagen and elastic fibers using whole-slide images of liver biopsy specimens	Pathol Int.	63	305-310	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H</u>	Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.	Gut Liver.	7	246-251	2013
Ogura S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, <u>Kumada H</u>	Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral disease.	Hepatol Res.	43	836-845	2013
Urabe Y, Ochi H, <u>Kumada H</u> , Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo PH, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyoya J, Kubo M, Chayama K., Nakamura Y, Matsuda K	A genomu-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region	J Hepatol.	58	875-882	2013
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u>	Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis	Intervirolology.	56	37-45	2013
Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K. <u>Kumada H</u>	Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.	Intervirolology.	56	13-21	2013
Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Tsubouchi H, <u>Kumada H</u>	Discrimination of fibrotic Staging of chronic hepatitis C using multiple fibrosis markers.	Hepatol Res.	Epub ahead of print		2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sezaki H, Suzuki F, Hosaka T, Akuta N, Fukushima T, Hara T, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikreda K, <u>Kumada H</u>	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients	Hepatol Res.		Epub ahead of print	2014
Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, SWhima T, <u>Okanoue T</u> , Itoh Y	Prediction of favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study	Hepatol Res	43	557-562	2013
Mitsuyoshi H, Yasui K, Yamaguchi K, Minami M, <u>Okanoue T</u> , Itoh Y	Pathogenic role of iron deposition in reticuloendothelial cells during the development of chronic hepatitis C	Int J Hepatol	6864 20		2013
<u>J.Toyota</u> , I.Ozeki, Y.Karino, Y.Asahina, N.Izumi, S.Takahashi, Y.Kawakami, K.Chayama, N.Kamiya, K.Aoki, I.Yamada, Y.Suzuki, F.Suzuki and H.Kumada	Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b	J.Viral Hep.	20	167-173	2013
Y.Karino, <u>J.Toyota</u> , K.Ikeda, F.Suzuki, K.Chayama, Y.Kawakami, H.Isikawa, H.Watanabe, D Hernandez, F.Yu, F.McPhee and H.Kumada	Characterization of virological escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir	J.Hepatol.	58	646-654	2013
小関 至、髭 修平、狩野吉康、木村睦海、荒川智宏、中島知明、桑田靖昭、大村卓味、佐藤隆啓、 <u>豊田成司</u>	B型慢性肝疾患における核酸アナログ多剤耐性例の検討	日本消化器病学会雑誌	1	44-55	2013
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, <u>Takehara T.</u>	Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. J Gastroenterol. in press	J Gastroenterol.		Doi 10.1007/s00535-013-0824-z	2014

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakusijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, <u>Takehara T.</u>	Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.	J Viral Hepat.		Doi:10.1111/1/jvh12151	2014
Ikeda K, Izumi N, Tanaka E, <u>Yotsuyanagi H</u> , Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Tsubouchi H, Kumada H.	Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.	Hepatol Res		doi: 10.1111/he pr.12221.	2014
Ito K, <u>Yotsuyanagi H</u> , Yatsushashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group.	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59	89-97	2014
<u>Yotsuyanagi H</u> , Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K.	High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B.	Clin Infect Dis.	57	935-42	2013
Okazaki T, Yamazaki K, Iwasaki T, Okano T, Kurosaki Y, Nakamura K, Fujioka T, Yotsuyanagi H.	α 2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C.	Clin Chem Lab Med.	51	e17-8	2013
Ikeda K, Izumi N, Tanaka E, <u>Yotsuyanagi H</u> , Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Kumada H.	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B.	Hepatol Res.	42	1236-40	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okuse C, <u>Yotsuyanagi H</u> , Yamada N, Ikeda H, Kobayashi M, Fukuda Y, Takahashi H, Matsunaga K, Matsumoto N, Okamoto M, Ishii T, Sato A, Koike K, Suzuki M, Itoh F.	Changes in levels of hepatitis B virus markers in patients positive for low-titer hepatitis B surface antigen.	Hepatol Res.	42	1236-40	2012
Tamaki N, <u>Kurosaki M</u> , Tanaka K, Suzuki Y, Hoshioka Y, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Izumi N	Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C	J Viral Hepat	20	72-76	2013
Nozawa Y, Umemura T, Katsuyama Y, Shibata S, Kimura T, Morita S, Joshita S, Komatsu M, <u>Matsumoto A</u> , Yoshizawa K, Ota M, Tanaka E.	Genetic polymorphism in IFNL4 and response to pegylated interferon- α and ribavirin in Japanese chronic hepatitis C patients.	Tissue Antigens.	83	45-48	2014
Nozawa Y, Umemura T, Joshita S, Katsuyama Y, Shibata S, Kimura T, Morita S, Komatsu M, <u>Matsumoto A</u> , Tanaka E, Ota M.	KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan.	PLoS One.	8	e83381	2013
Suzuki Y, Ikeda K, <u>Suzuki F</u> , Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, McPhee F, Eric Hughes, Kumada H	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options	J Hepatol.	58	655-662	2013
Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, <u>Suzuki F</u> , Kumada H	Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b	J Viral Hepat.	20	167-173	2013
Tadokoro K, Kobayashi M, <u>Suzuki F</u> , Tanaka C, Yamaguchi T, Nagano M, Egashira T, Kumada H	Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay	J Virol Methods.	189	221-227	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arase Y, Kobayashi M, <u>Suzuki F</u> , Tanaka C, Yamaguchi T, Nagano M, Egashira T, Kumada H	Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C	Hepatology.	3	964-973	2013
Karino Y, Toyota J, Ikeda K, <u>Suzuki F</u> , Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Dennis Hernandez, Fei Yu, Fiona McPhee, Kumada H	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir	J Hepatol.	58	646-654	2013
Hirakawa M, Ikeda K, Kobayashi M, Kawamura Y, Hosaka T, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Arase Y, Kumada H	Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle hepatocellular carcinoma	Hepatol Res.	43	846-852	2013
<u>Suzuki F</u> , Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H	Exploratory Study on telaprevir given every 8h at 500mg or 750mg with peginterferon-alpha-2b and rivavirin in hepatitis C patients	Hepatol Res.	43	691-701	2013
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection	Hepatology.	58	98-107	2013
Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Emergence of Telaprevir-Resistant Variants Detected by Ultra-Deep Sequencing After Triple Therapy in Patients Infected With HCV Genotype 1	J Med Virol.	85	1028-1036	2013
Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H	Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis	Hepatol Int.	7	850-858	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Kumada H	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma	Hepatol Res.	43	942-949	2013
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Seko Y, kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study	J Gastroenterol.	48	930-941	2013
Akuta N, <u>Suzuki F</u> , Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1	J Clin Microbiol.	51	2862-2868	2013
<u>Suzuki F</u> , Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine	J Gastroenterol.		Epub ahead of print	2013
Akuta N, <u>Suzuki F</u> , Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Utility of Telaprevir-Resistant Variant Detection for Prediction of Treatment Efficacy n HCV Genotype 1.	J Clin Microbiol.		Epub ahead of print	2013
Kawakami Y, <u>Suzuki F</u> , Karino Y, Toyota J, Kumada H, Chayama K	Telaprevir is effective given every 12 houes at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antivir Ther.		Epub ahead of print	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arase Y, Kobayashi M, Kawamura Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T	Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.	J Med Virol.	86	169-175	2014
Akuta N, <u>Suzuki F</u> , Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis	J Med Virol.	Epub ahead of print		2013
Hosaka T, <u>Suzuki F</u> , Kumada H	Does long-term entecavir treatment really reduce hepatocellular carcinoma incidence in patients with hepatitis B virus infection?	Hepatology.	Epub ahead of print		2013
Kawakami Y, Ikeda K, Fukushima T, Hara T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H	Potential of no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: an experimental animal study.	Hepatol Res.	Epub ahead of print		2013
Kawamura Y, Ikeda K, Fukushima T, Seko Y, Hara T, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H	What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.	Gut Liver.	5	576-584	2013
Hara T, Akuta N, <u>Suzuki F</u> , Sezaki H, Suzuki Y, Hosaka, Kobayashi M, Saitoh, Kumada H	A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic Hepatitis C.	J Med Virol.	85	1746-1753	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kobayashi M, Hosaka T, <u>Suzuki F</u> , Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up	J Gastroenterol.		Epub ahead of print	2013
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H	Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.	Gut Liver.	7	246-251	2013
Ogura S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, <u>Suzuki F</u> , Suzuki Y, Arase Y, Ikeda K, Kumada H	Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral disease.	Hepatol Res.	43	836-845	2013
Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis	Intervirology.	56	37-45	2013
Seko Y, Akuta N, <u>Suzuki F</u> , Kawamura Y, Sezaki H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.	Intervirology.	56	13-21	2013
Sezaki H, <u>Suzuki F</u> , Hosaka T, Akuta N, Fukushima T, Hara T, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients	Hepatol Res.		Epub ahead of print	2014
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Tokunaga K, Mizokami M, Izumi N.	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C	J Med Virol	85 (3)	449-458	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N.	Deep-Sequencing Analysis of the Association between the Quasispecies Nature of the Hepatitis C Virus Core Region and Disease Progression	J. Virol.	87	12541-12551	2013
Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Enomoto N.	Deep sequencing analysis of variants resistant to the NS5A inhibitor daclatasvir in patients with genotype 1n hepatitis C virus infection.	Hepatol Res	in press		2014
<u>Kawakami Y</u> , Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K.	Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antivir Ther.			2014
Fujino H, Imamura M, Nagaoki Y, <u>Kawakami Y</u> , Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group.	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.	J Gastroenterol.			2014
T. Nishikawa, S. Hashimoto, N. Kawabe, M. Harata, Y. Nitta, M. Murao, T. Nakano, Y. Mizuno, H. Shimazaki, T. Kan, K. Nakaoka, Y. Takagawa, M. Ohki, N. Ichino, K. Osakabe, <u>K. Yoshioka</u> .	Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C	World J Gastroenterol.	20(5)	1289-1297	2014

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
K. Hayashi, Y. Katano, H. Masuda, Y. Ishizu, T. Kuzuya, T. Honda, M. Ishigami, A. Itoh, Y. Hirooka, I. Nakano, T. Ishikawa, F. Urano, <u>K. Yoshioka</u> , H. Toyoda, T. Kumada and H. Goto	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B	Hepatol Res	43(6)	580-8	2013
<u>K. Yoshioka</u>	What is the benefit of computer-assisted image analysis of liver fibrosis area?	J Gastroenterol	48(8)	996-7	2013
<u>K. Yoshioka</u>	How to adjust the inflammation-induced overestimation of liver fibrosis using transient elastography?	Hepatol Res	43(2)	182-4	2013
Maeshima K, Ishii K, Inoue M, Himeno K, <u>Seike M.</u>	Behçet's disease complicated by multiple aseptic abscesses of the liver and spleen.	World J Gastroenterol	28	3165-8	2013
Gotoh K, Inoue M, Masaki T, Chiba S, Shiraishi K, Shimasaki T, Matsuoka K, Ando H, Fujiwara K, Fukunaga N, Aoki K, Nawata T, Katsuragi I, Kakuma T, <u>Seike M.</u> Yoshimatsu H.	Obesity-related chronic kidney disease is associated with spleen-derived IL-10.	Nephrol Dial Transplant	28	1120-1130	2013
Inoue M, Gotoh K, <u>Seike M.</u> , Masaki T, Oribe J, Honda K, Kakuma T, Yoshimatsu H.	High alanine aminotransferase level as a predictor for the incidence of macrovascular disease in type 2 diabetic patients with fatty liver disease	Hepatol Int.	7	551-561	2013
渡辺久剛、 <u>上野義之</u>	B型肝炎の自然予後（無治療住民検診での長期予後）	肝胆膵	66(3)	399-407	2013